New drug cocktail aims to tackle myeloma that resists CAR-T therapy
NCT ID NCT07612787
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of two drugs, belantamab mafodotin and mezigdomide, in 44 adults with multiple myeloma whose cancer returned after treatment with CAR-T cells or bispecific antibodies. The goal is to see if the combo can control the cancer longer. The trial starts with a safety check (Phase 1b) before moving to the main Phase 2 part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- belantamab mafodotin and mezigdomide
- What this could lead to
- If successful, this combination could offer a new treatment option for multiple myeloma patients who have stopped responding to other advanced therapies.
- What could go wrong
- This is an early-phase trial with only 44 participants, so results may not apply to all patients. The drugs can cause side effects like eye problems and low blood counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOMA MULTIPLE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
APHP - La Pitié Salpétrière
Paris, 75013, France
-
Centre Henri Becquerel
Rouen, 76038, France
-
Centre Hospitalier
Le Mans, 72037, France
-
Centre Hospitalier D'Argenteuil
Argenteuil, 95107, France
-
Centre Hospitalier Regional Et Universitaire
Nancy, 54500, France
-
Centre Hospitalier Universitaire
Amiens, 80000, France
-
Centre Hospitalier Universitaire
Angers, 49100, France
-
Centre Hospitalier Universitaire
Annecy, 74370, France
-
Centre Hospitalier Universitaire
Brest, 29200, France
-
Centre Hospitalier Universitaire
Caen, 14008, France
-
Centre Hospitalier Universitaire
Clermont-Ferrand, 63003, France
-
Centre Hospitalier Universitaire
Dijon, 21000, France
-
Centre Hospitalier Universitaire
Grenoble, 38700, France
-
Centre Hospitalier Universitaire
Lille, 59000, France
-
Centre Hospitalier Universitaire
Limoges, 87000, France
-
Centre Hospitalier Universitaire
Nantes, 44093, France
-
Centre Hospitalier Universitaire
Nice, 06000, France
-
Centre Hospitalier Universitaire
Orléans, 45100, France
-
Centre Hospitalier Universitaire
Paris, 75010, France
-
Centre Hospitalier Universitaire
Saint-Etienne, 42055, France
-
Centre Hospitalier Universitaire
Tours, 37000, France
-
Centre Hospitalier de La Cote Basque
Bayonne, 64100, France
-
Centre Hospitalier de Poitiers
Poitiers, 86000, France
-
HCL Lyon-Sud
Lyon, 69000, France
-
Hopital Cochin
Paris, 75014, France
-
Hopital St Antoine
Paris, 75012, France
-
Hôpital Privé de Confluent
Nantes, 44000, France
-
ICANS
Strasbourg, 67200, France
-
IUCT
Toulouse, 31100, France
-
Institut Bergonié
Bordeaux, 33076, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo outsmart resistant myeloma?
- Real-world data on multiple myeloma immunotherapies could reshape monitoring and improve survival
- Could an ALS drug clear the fog of chemo brain?
- Immune cell 'Fitness' may predict success of advanced myeloma therapies in older patients
- Gene clues may unlock new treatments for bone marrow cancer
- New study monitors infection risks in blood cancer patients on bispecific antibodies